Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

An Overview of Endometrial Cancer

June 20th 2023

Christian Marth, MD, PhD, discusses the prevalence of endometrial cancer, as well as the steps that lead to diagnosis.

Institutional Perspectives in Cancer: Gynecologic Cancers - Chaired by Michael James Birrer, MD, PhD

June 13th 2023

Institutional Perspectives in Cancer: Gynecologic Cancers - Chaired by Michael James Birrer, MD, PhD

Majority of US Cancer Centers Report Shortages of Cisplatin/Carboplatin Chemotherapy

June 7th 2023

A survey conducted by the National Comprehensive Cancer Network Best Practices Committee found that 93% of United States cancer centers polled in the report are experiencing a shortage of carboplatin, and 70% currently have a shortage of cisplatin.

FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer

June 6th 2023

The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Gaining Ground in Gynecologic and Hematologic Cancers at ASCO 2023: Drs Herrera, Westin, and Jabbour

June 5th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

PRO Outcomes With Dostarlimab/Chemo Similar to Chemo Alone in 3-Year Follow-Up of Patients With Endometrial Cancer

June 4th 2023

Dostarlimab maintained the health-related quality of life in patients with primary advanced or recurrent endometrial cancer.

Mirvetuximab Soravtansine Positioned as New Standard in Frα+ Platinum-Resistant Ovarian Cancer

June 4th 2023

Mirvetuximab soravtansine-gynx demonstrated a 35% reduction in the risk of disease progression or death compared with investigator’s choice of chemotherapy in patients with folate receptor alpha-high, platinum-resistant ovarian cancer.

Dostarlimab Plus Chemo Leads to PFS Improvement in dMMR/MSI-H Advanced Endometrial Cancer

June 4th 2023

The combination of dostarlimab with standard-of-care carboplatin and paclitaxel elicited a statistically significant and clinically meaningful improvement in progression-free survival vs carboplatin/paclitaxel plus placebo in patients with mismatch repair–deficient/microsatellite instability–high advanced or recurrent endometrial cancer.

Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical Cancer

June 2nd 2023

Simple hysterectomy was found to be noninferior to radical hysterectomy and pelvic node dissection in patients with low-risk, early-stage cervical cancer, according to results of the Canadian Cancer Trials Group CX.5/SHAPE trial.

Dr Girda on the Use of Pembrolizumab Plus Chemotherapy in Endometrial Cancer

May 30th 2023

Eugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.

Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer

May 26th 2023

The combination of durvalumab and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus olaparib or durvalumab alone, elicited a statistically significant and clinically meaningful improvement in progression-free survival in patients with newly diagnosed, advanced or recurrent endometrial cancer.

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

May 25th 2023

Pembrolizumab plus chemotherapy with or without bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the KEYNOTE-826 trial.

Clinical Trials in Endometrial Cancer Need Improved Diversity to Address Rising Mortality Rates

May 25th 2023

Bhavana Pothuri, MD, expands on challenges that still need to be addressed for the treatment of patients with endometrial cancer, highlights potential practice-changing data from the phase 3 NRG-GY018 and RUBY trials, details the evolving role of PARP inhibitors for patients with ovarian cancer, and touches on key emerging data from trials for patients with cervical cancer.

NICE Recommends Pembrolizumab Plus Lenvatinib for Previously Treated Advanced or Recurrent Endometrial Cancer

May 22nd 2023

The National Institute for Health and Care Excellence has recommended the combination of pembrolizumab and lenvatinib for use in previously treated patients with advanced or recurrent endometrial cancer whose cancer has progressed on or after platinum-based chemotherapy and who cannot have curative surgery or radiotherapy.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Institutional Perspectives in Cancer: Gynecologic Cancers - Chaired by Rachel Grisham, MD

May 18th 2023

Institutional Perspectives in Cancer: Gynecologic Cancers - Chaired by Rachel Grisham, MD

Dr Naumann on the Changing Treatment Landscape in Cervical Cancer

May 16th 2023

R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.

State of Science Summit- Gynecologic Cancer: Chaired By Bhavana Pothuri, MD | NYU Langone’s Perlmutter Cancer Center

May 2nd 2023

State of Science Summit- Gynecologic Cancer: Chaired By Bhavana Pothuri, MD | NYU Langone’s Perlmutter Cancer Center

EMA Validates Type II Variation Application for Dostarlimab/Chemo for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

April 25th 2023

The European Medicines Agency has validated a type II variation for potential approval of dostarlimab in combination with carboplatin and paclitaxel for the treatment of patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

PARP Inhibitors, ADCs, and Immunotherapy Approaches Advance the Treatment Paradigm in Gynecologic Oncology

April 24th 2023

Joshua G. Cohen, MD, FACOG, FACS, expands on the role of PARP inhibitors in the recurrent and up-front settings in ovarian cancer, and the clinical significance of the RUBY and NY-GY018 trials in endometrial cancer.